丹参酮Ⅰ对2型糖尿病ICR小鼠抗糖作用的研究

发布时间：2018-04-22 15:51

本文选题：型糖尿病 + 丹参酮Ⅰ　；参考：《安徽医科大学学报》2016年09期

【摘要】：目的观察丹参酮Ι对高脂高糖饮食结合多次小剂量链脲佐菌素(STZ)注射诱导的2型糖尿病(T2DM)模型ICR小鼠肝脏的影响并分析其可能的作用机制。方法制备小鼠T2DM模型,随机分为模型组、丹参酮Ι(高剂量、中剂量、低剂量)组、二甲双胍(Met)组和吡格列酮(Pio)组,随后这6组继续给于高脂高糖饲料喂养3周,每天注射相应浓度的药物,同时,对7组(包括正常组)小鼠每周测一次空腹血糖和体重。3周末,取小鼠肝脏,运用HE染色观察各组的病理变化,免疫组化法和Western blot法检测各组蛋白酪氨酸磷酸酶1B(PTP1B)、蛋白激酶B(Akt)、P-Akt蛋白表达水平。结果丹参酮Ι高剂量组可以降低T2DM ICR小鼠的血糖(P0.05),增加其体重(P0.05)。丹参酮Ι3个剂量组肝组织中未见明显细胞质肿胀和细胞核固缩现象,且组织中炎症较轻。免疫组化法结果显示,丹参酮Ι高剂量组可以降低T2DM ICR小鼠肝脏组织中PTP1B蛋白的表达(P0.05)。Western blot法显示,丹参酮Ι中剂量组和高剂量组可以降低T2DM ICR小鼠肝脏组织中PTP1B蛋白的表达(P0.05),各组中Akt的表达均无明显差异,丹参酮Ι高剂量组可以提高T2DM小鼠肝脏中P-Akt的蛋白表达(P0.05)。结论高剂量的丹参酮Ι可以降低STZ诱导的T2DM小鼠的空腹血糖水平和肝损伤,同时降低肝脏PTP1B的表达,提高肝脏P-Akt的表达。
[Abstract]:Objective to observe the effect of tanshinone I on the liver of type 2 diabetes mellitus (T2DM) model ICR mice induced by high fat and high glucose diet combined with low dose streptozotocin (STZ) injection and to analyze its possible mechanism. Methods T2DM mice were randomly divided into three groups: model group, tanshinone group (high dose, middle dose, low dose group), metformin group and pioglitazone group. The 6 groups were fed with high fat and high sugar diet for 3 weeks. At the same time, fasting blood glucose and body weight were measured once a week in 7 groups of mice (including normal group) every week. The liver of mice was taken and the pathological changes of each group were observed by HE staining. The expression of protein tyrosine phosphatase (1BX) PTP1BX, protein kinase B (PKB) and protein kinase (PKB) were detected by immunohistochemical method and Western blot method. Results tanshinone I high dose group could decrease the blood glucose of T2DM ICR mice and increase their body weight. In the three dose groups of tanshinone I, there was no obvious cytoplasmic swelling and nuclear pyknosis, and the inflammation was mild. The results of immunohistochemistry showed that tanshinone I could decrease the expression of PTP1B protein in the liver of T2DM ICR mice. Tanshinone I medium dose group and high dose group could decrease the expression of PTP1B protein in the liver of T2DM ICR mice. There was no significant difference in the expression of Akt in all groups. Tanshinone I high dose group could increase the expression of P-Akt protein in the liver of T2DM mice. Conclusion the high dose tanshinone I can decrease the level of fasting blood glucose and liver injury in T2DM mice induced by STZ, decrease the expression of PTP1B in liver and increase the expression of P-Akt in liver.
【作者单位】：安徽医科大学药学院;安徽医科大学肝病研究所;安徽省创新药物产业共性研究院;
【基金】：国家自然科学基金(编号:81473268、81273526) 高等学校博士学科点专项科研基金(编号:20123420120001) 安徽省自然科学基金(编号:1408085MKL31) 安徽省科技攻关计划项目(编号:1301042212)
【分类号】：R587.1

【相似文献】